Stockscreener 앱 받기
11.13
3.30%
-0.38
시장 영업 전:
11.29
0.16
+1.44%
Novocure Ltd 주식(NVCR)의 최신 뉴스
Statistical indicators supporting NovoCure Limited’s strengthFree High Accuracy Alerts for ROI Traders - Newser
NovoCure's Optune Study for Glioblastoma Treatment: A Potential Game-Changer in the Market - AInvest
Is NovoCure Limited trending in predictive chart modelsAsset Growth Pattern and Return Summary - Newser
Short interest data insights for NovoCure LimitedTechnical Confirmation System with Signal Alerts - Newser
Detecting price anomalies in NovoCure Limited with AILow Drawdown Stock Screener with Analysis - Newser
NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer? - TipRanks
Real time scanner hits for NovoCure Limited explainedAI Short-Term Gain Forecast with Data - Newser
How institutional ownership impacts NovoCure Limited stockFree Triple Digit Return Stock Predictions - Newser
How strong is NovoCure Limited company’s balance sheetRapid wealth multiplication - Jammu Links News
What are analysts’ price targets for NovoCure Limited in the next 12 monthsCapitalize on emerging market sectors - Jammu Links News
How volatile is NovoCure Limited stock compared to the marketBreakthrough profit margins - Jammu Links News
Is NovoCure Limited stock poised for growthAnnual Market Behavior and Sector Summary - Newser
Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares - simplywall.st
NovoCure (NVCR) Sales Rise but Losses Deepen—Is Profitability or Growth the Bigger Priority? - simplywall.st
NovoCure (NASDAQ:NVCR) Shares Up 9.3% After Insider Buying Activity - Defense World
Novocure’s Earnings Call: Clinical Successes & Cautious Optimism - TipRanks
NovoCure CFO Makes a Bold Move: Christoph Brackmann Purchases $231,800 Worth of Stock - AInvest
NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha
Will NovoCure Limited stock benefit from AI tech trendsWeekly Entry Signal Based Forecast Tool - Newser
Multi asset correlation models including NovoCure LimitedFree Low Risk Buy Zone Opportunity Watch - Newser
Why NovoCure Stock Is Cratering Today - Mitrade
NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call Transcript - Insider Monkey
Does NovoCure Limited show high probability of reboundSafe Entry Strategy with High Win Rate - Newser
What are NovoCure Limited company’s key revenue driversDiscover undervalued stocks before they soar - Jammu Links News
Top 3 Health Care Stocks That May Explode In July - inkl
Wells Fargo & Company Reaffirms Equal Weight Rating for NovoCure (NASDAQ:NVCR) - Defense World
NovoCure Q2 2025 Earnings Highlights: Revenue Growth Amidst Challenges - AInvest
NovoCure Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
NovoCure: Q2 Earnings Snapshot - Norwalk Hour
NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha
Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38 - 富途牛牛
NovoCure Limited Stock Analysis and ForecastBreakneck growth rates - Autocar Professional
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Gr - GuruFocus
Novocure: Wells Fargo downgrades to Equal-Weight, PT reduced to $14.5. - AInvest
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
Novocure Ltd. Reports Q2 2025 Financial Results - TipRanks
Novocure Beat Revenue Expectations As Patient Numbers Grew - Finimize
How NovoCure Limited stock performs during market volatilityTargeted 200 Percent Gain - Newser
1.17%
자본화:
|
볼륨(24시간):